Corline Biomedical: Q4 Review

Research Note

2021-03-01

10:08

Redeye reiterates its positive view and Base case of SEK 39 per share following Corline’s Q4 report. We provide a brief comment on the financials and highlight the most important events during the period.

LS

Ludvig Svensson

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.